Cipro is only one killer of many in the fuoroquinolone class antibiotics!
As some of you may know, I have filed at the FDA a Citizen’s Petition again the antibiotic drug class fluoroquinolones, the most frequently prescribed antibiotics today. I started my attack with Cipro as guilty #1 since that is what nearly everyone gets and the number of people getting sick from Cipro is staggering. Cipro is now also understood to be the cause of the Gulf War Syndrome since soldiers were mandated to take it every day against anthrax in the field.
Many people have been permanently injured–some even have committed suicide. I am a firm believer that fibromyalgia is yet one more of the diseases we may be able to point to this class of drugs. The citizen petition docket is still open.
I just received a letter from the FDA stating that the matter is so complex that they…
View original post 71 more words
The leading theory for why the blood of younger mice rejuvenates the muscles of older mice is now in contest. The vampiric exchange of young blood and old blood has long been reported to have anti-aging effects, but it was in 2013 when Harvard University researchers first linked GDF-11, a molecule that circulates in the blood, to this effect.
Now, an analysis that set out to see how GDF-11 works in the muscles published May 19 in Cell Metabolism found just the opposite. The investigators showed first that GDF-11 was not specifically measured; the methods that were previously used were not specific for GDF-11, but also measured another molecule it closely resembles, called myostatin, which is well known to inhibit muscle growth.
The new study, led by David Glass at the Novartis Institutes for BioMedical Research, in collaboration with Massachusetts General Hospital and the University of California, San Francisco, used tests to more accurately measure GDF-11 (short for Growth Differentiation Factor 11) in the blood of animals and humans and found that it showed hints of increasing with age, and clearly did not decrease with age. They also show that regularly injecting mice with pure GDF-11 causes muscle repair to worsen, resembling effects seen in older age.
“This is a carefully conducted study that is certain to generate a vigorous discussion about what role GDF-11 plays, if any, in aging muscle,” says Se-Jin Lee, an expert on growth/differentiation factors and molecular biologist at Johns Hopkins University who did not participate in the research.
“I think that these new results definitely raise questions as to whether GDF-11 was really being exclusively detected in the prior paper,” Lee adds. “Clearly, these discrepancies will need to be resolved with additional studies, especially given the enormous effort being undertaken in the pharmaceutical community to target the myostatin pathway to treat muscle loss.”
Giving GDF-11 at doses previously used in aged animals did not improve regeneration, as previously claimed. When younger animals were treated with GDF-11, regeneration was worsened. The authors developed a test that could detect GDF-11 levels specifically and suggest that, for humans, testing for high levels of GDF-11 could potentially make them eligible for medicines that block GDF-11 activity.
“Clearly, like the mythical fountain of youth, GDF11 is not the long sought rejuvenation factor,” write Caroline Brun and Michael A. Rudnicki of the Ottawa Hospital Research Institute in a preview to the Cell Metabolism paper. They say, given these new findings, “the suggested ‘rejuvenating’ activity of GDF11 in the heart and brain should also be re-examined – since the underlying premise of those other two manuscripts, that GDF11 decreases with age, is contradicted by [the new] manuscript.”
Painful knee arthritis is associated with an increased risk of premature death in women, a new study suggests.
Women with osteoarthritis-related knee pain— the type associated with normal wear and tear — were nearly twice as likely to die early from any cause, and more than three times as likely to die from heart problems as those without knee pain from arthritis, the British researchers found.
“These findings suggest that any self-reported knee pain in osteoarthritis, as opposed to hand pain, seems to be a crucial factor leading to early cardiovascular mortality and is likely to be linked with decreased mobility,” said lead author Dr. Stefan Kluzek of the Arthritis Research UK Centre of Excellence for Sport, Exercise and Osteoarthritis at the University of Oxford.
There was no increased risk of early death among women with osteoarthritis pain in the hands. Nor did women with X-ray evidence of knee arthritis but no pain have an increased risk of premature death, the study found.
Researchers analyzed data from middle-aged British women who were tracked for an average of 22 years.
The study is scheduled for presentation Friday at the World Congress onOsteoporosis, Osteoarthritis and Musculoskeletal Diseases in Milan, Italy. Data and conclusions presented at meetings are usually considered preliminary until published in a peer-reviewed medical journal.
“More research is needed to understand how people adapt to knee pain, and how this leads to cardiovascular impairment,” Kluzek said in a news release from the International Osteoporosis Foundation.
— Robert Preidt
Medication used to treat patients with type II diabetes activates sensors on brain cells that increase hunger, causing people taking this drug to gain more body fat, according to researchers at Georgia State University, Oregon Health and Science University, Georgia Regents University and Charlie Norwood Veterans Administration Medical Center.
The study, published on March 18 in The Journal of Neuroscience, describes a new way to affect hunger in the brain and helps to explain why people taking a class of drugs for type II diabetes gain more body fat.
Type II diabetes, the most common form of diabetes, affects 95 percent of diabetes sufferers. People with type I or type II diabetes have too much glucose, or sugar, in their blood. Type II diabetes develops most often in middle-aged and older adults and people who are overweight and inactive, according to the National Institute of Diabetes and Digestive and Kidney Diseases.
The research team found that sensors in the brain that detect free circulating energy and help use sugars are located on brain cells that control eating behavior. This is important because many people with type II diabetes are taking antidiabetics, known as thiazolidinediones (TZDs), which specifically activate these sensors, said Johnny Garretson, study author and doctoral student in the Neuroscience Institute and Center for Obesity Reversal at Georgia State.
The study found peroxisome proliferator-activated receptor ϒ (PPARϒ) sensors on hunger-stimulating cells, known as agouti-related protein (AgRP) cells, at the base of the brain in the hypothalamus. Activating these PPARϒ sensors triggers food hoarding, food intake and the production of more AgRP. When AgRP cells are activated, animals become immediately hungry. These cells are so potent they will wake a rodent up from slumber to go eat, Garretson said.
TZDs help to treat insulin resistance, in which the body doesn’t use insulin the way that it should. They help the body’s insulin work properly, making blood glucose levels stay on target and allowing cells to get the energy they need, according to the National Institute of Diabetes and Digestive and Kidney Diseases.
“People taking these TZDs are hungrier, and they do gain more weight. This may be a reason why,” Garretson said. “When they’re taking these drugs, it’s activating these receptors, which we believe are controlling feeding through this mechanism that we found. We discovered that activating these receptors makes our rodent animal model eat more and store more food for later, while blocking these receptors makes them eat less and store less food for later, even after they’ve been food deprived and they’re at their hungriest.”
Georgia State University
Ready for this? A baby girl was born “pregnant” with 8- to 10-week-old twin fetus-like structures, ABC News reports. The baby was born in November 2010, and researchers are just now releasing their findings that what was thought to be a set of tumors in her abdomen were actually fetuses. They weighed in at half an ounce and a third of an ounce and were developmentally far enough along that they each had four limbs, a spine, a rib cage, intestines, and an anus.
The nearly 9-pound “pregnant” baby underwent a successful surgery to remove the fetuses when she was just 2 weeks old. The condition is known as fetus in fetu, and there have been 200 documented incidences — ever. Fetus in fetu occurs when a partially-developed fetus (or in this case, two of them) becomes incorporated into a normally-developing fetus within the womb. Can you imagine!?
Author: Lisa Horten
Eli Lilly the world’s first insulin maker has been entitled by the
European Commission for marketing Trulicity (dulaglutide), a novel injectable treatment for adults with type 2 diabetes. The once-weekly Trulicity may affect the Novo Nordisk’s widely used blockbuster Victoza (liraglutide) as it has demonstrated clinical superiority however there are safety concerns based on pre-clinical lab data which may result in an uncertain sales outcome in view of upcoming approvals from other companies.
Trulicity is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed in an easy-to-use single-dose pen and can be taken any time of day, with or without meals. Studies reveal that Trulicity can help in lowering the A1C and blood sugar numbers and may even help to lose some weight. GLP-1 is a natural hormone, in prodding the body to release insulin when patients eat. Like other insulin products Trulicity can cause hypoglycemia, nausea, fainting and other symptoms and is contraindicated in thyroid patients.
Diabetes (type 1 and 2) is a chronic disease in which the body either does not properly produce, or use, the hormone insulin. It victimizes 29 million Americans and 382 million people around the globe with 90-95% occurrence of Type 2.
Launched in 2009, Victoza reached 2.3 million patients globally with a blockbuster sale of $418 million in 2010 and doubling to $1.04 billion in the first half of 2013. The analysts estimate the sales to quadruple to $4.07 billion in 2018. Tim Anderson, Bernstein analyst forecasts the sale of Trulicity to reach $1.3 billion by 2020. The current market of GLP-1 is around $3 billion.
Last year GlaxoSmithKline’s Tanzeum was approved by the FDA which is also a once-weekly GLP-1 agonist but unlike Trulicity Tanzeum failed to show superiority to Victoza. AstraZeneca after acquiring the Byetta from the dead alliance of the inventors Amylin and Eli Lilly launched Bydureon, which is another once-weekly treatment but it failed due to complicated delivery system, however approval for a new delivery system for Bydureon was received earlier this year. Merck’s DPP-4 inhibitor Januvia, Sanofi’s Lyxumia (lixisenatide) and AstraZeneca’s once-a-month version in the pipeline is yet another reason for Trulicity to worry.
Although While Trulicity has been found as non-inferiorsuperior to blockbuster Victoza in head-to-head trials, its fate is dilemmatic with robust rivals anduncertain as there is a major concern of drug safety as per its black box warning regardingdue to increased risk for thyroid C-cell tumors based on pre-clinical studies. The stakes are high and the diabetes patient population is large so the outcome remains to be seen specially in view of the oncoming competition.
|S. NO||APPROVED DRUG||INDICATION||APPROVAL DATE|
|1||Tolterodine Tartrate Extended release tablets 2mg/4mg (Additional Dosage Form)||For the treatment of overactive bladder with symptoms of urge urinary incontinence, urinary incontinence, urgency and frequency.||31.01.14|
|2||Bortezomib for injection 3.5mg (Sub-cutaneous route of administration as an alternate to intravenous route) (Additional route of administration)||Same as already approved||28.01.14|
|3||Paclitaxel Injection Concentrate for Nanodispersion 100mg and 300mg (Additional Dosage Form)||For the treatment of Breast cancer after failure of combination therapy metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.||22.01.14|
|4||Heparin Sodium Topical Solution 1000 IU/ml (Additional Dosage Form)||For the management of post infusion superficial thrombophlebitis.||16.1.2014|
|5||Simethicone Orally disintegrating strip 62.5mg||For the treatment of flatulance and as adjuvant in hyperacidity.||14.11.2010|
|6||Eltrombopag Olamine tablet 25/50mg (Additional Indication)||Indicated in patients with chronic hepatitis C Virus (HCV) infection for the treatment of thrombocytopenia to: Enable the initiation of interferon based therapy, optimise interferon based therapy.||07.04.2014|
|7||Decitabine lyophilised powder for injection 50mg/20ml vial (additional indication)||For the treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary acute myeloid leukemia (AML), according to World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.||09.04.2014|
|8||Glycopyrronium bromide inhalation powder hard capsule with inhaler. Each capsule contains 63mcg Glycopyrronium bromide eq. to Glycopyrronium 50 mcg.||Indicated as a once daily maintenance bronchodilator treatment to relieve symptoms of patients with Chronic Obstructive Pulmonary Disease (COPD).||01.04.2014|
|9||Micafungin sodium for injection 100mg/vial (Additional Strength)||Treatement of patient with candidemia,acute Disseminated Candidiasis, Candida Peritonitis and abscesses.Treatment of patients with Esophageal Candidiasis,Prohylaxis of Candidia and Aspergillus Infections in patients undergoing Hemopoeitic stem cell transplantaion.Treatment of patient with Fungemia, Respiratory mycosis, Gastrointestinal mycosis caused by Aspergillus sp..||2.05.2014|
|10||Apixaban tablets 2.5mg/5mg (Additional Strength & Additional Indication)||Prevention of stroke and systemic embolism in adult patients with non-valvular artrial fibrillation (NVAF), including those with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA class≥II). Compared to warfarin apixaban also results in less bleeding, including intracranial hemorrhage.||16.05.2014|
|11||Mometasone furoate nasal spray 50 mcg/actuation (Additional Indication)||For the treatment of nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older.||21.05.2014|
|12||Micronised Purified Flavonoid 1000mg (MPFF). “Each film coated tablet contains diosmin 900mg and flavonoids expressed as Hesperidine 100 mg of Micronised Purified Flavonoid fraction of Rutaceae 1000mg (MPFF)”||Acute hemorrhoid piles||28.11.13|
|13||Gemcitabine HCl injection ready to use infusion bags
Gemcitabine HCL equivalent to Gemcitabine 10mg per mL
(100,120,130,140,150,160,170,180,190 and 200mL) (Approved as infusion bags)
|Ovarian cancer-Gemcitabine injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has replaced at least 6 months after completion of platinum based therapy. Breast Cancer-Gemcitabine injection in combination with Paclitaxel is indicated for the first line treatment of patients with metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclinces were clinically contraindicated. Non-small cell lung concer-Gemcitabine injection is indicated in combination with cisplatin for the first line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (stage IV) non-small cell lung cancer. Pancreatic cancer-Gemcitabine injection is indicated as first-line treatment for patient with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.Gemcitabine injection is indicated for patients previously treated with 5 -FU.||17.06.2014|
|14||Tadalafil Orally Disintegrating Strip 10mg & 20mg (Additional dosage form)||For erectile dysfunction||30.07.2014|
|15||Hydroxychloroquine Sulphate USP 400 mg tablets (Additional Indication)||As an adjunct to diet and exercise to improve glycemic control of patients on metformine, sulfonylurea combination in patients with Type II Diabetes.||28.07.2014|
|16||Nevirapine Extented release tablet 400mg (Additional Strength)||For use in combination with other anti-retroviral agents for the treatment of HIV-1 infection in adults||01.07.2014|
|17||Artesunate injection. Each combipack contains: “Artesunate for injection 120mg ( Each vial contains Artesunate IP 120mg), Sodium bicarbonate injection IP 5%w/v (Each 2ml ampoule contains: Sodium Bicarbonate IP 5% w/v), Sodium chloride Injection IP 0.9% w/v (Each 10ml ampoule contains: Sodium chloride IP 0.9% w/v)”||Promoted for use in severe malaria including cerebral malaria as a second line in chloroquine resistant malaria cases only.||13.11.2013|
|18||Cerebrolysin solution for injection. Each ml contains: Porcine brain derived peptide preparation (Cerebrolysine concentrate) 215.2mg||For amelioration of cranial injury, cerebrovascular pathological sequelae and aprosexia in dementia.||25.07.2014|
|19||Artesunate powder for injection 60mg/vial alongwith 6ml ampoule of phosphate buffer solution (pH 8.0;0.30M)||For the treatment of severe Falciparum malaria in areas where there is evidence if quinine resistance||02.07.2014|
|20||Montelukast sodium chewable tablet 4mg/5mg and Montelukast sodium film coated tablet 10mg.||As add on therapy in mild to moderate asthma inadequately controlled by inhaled corticosteroids and short active B2 agonist, Exercise induced bronchoconstriction.||26.02.2002|
|21||Lactobacillus brevis CD2 Lozenges 100mg (corresponding to not less than 1 billion) of live, lyophilised, lactic acid bacteria, Lactobacillus brevis CD2. (Additional indication)||Prevention of radiotherapy and chemotherapy induced oral mucositis in cancer patients.||08-09-2014|
|22||Rivaroxaban tablet 15/20mg (Additional strength/indication)||1. Treatment of deep vein thrombosis and for prevention of recurrent DVT and pulmonary embolism. 2. For the prevention of stroke and systemic embolism in patient with non-valvular arterial fibrillation.||2.9.14|
|23||Hydroxychloroquine Sulphate Tablet 300mg (Additional strength/indication)||Indicated for the treatment of patietns with lower body weight i.e 45 to 60kg in Rhemuatoid arthritis, Systemic Lupus Erythematosus & Polymorphic Light Eruption||08-09-2014|
|24||Ginkgo biloba extract Tablet 120mg (Additional strength)||For the treatment of dementia, vertigo and tinnitus in adult patients.||12-09-2014|
|25||Bendamustine Hydrochloride lyophilised injection 25mg (Additional strength)||Treatment of patients with chronic lymphocytic leukemia||19.9.2014|
|26||Metformin ER tablet 750mg (Additional strength)||As an adjunct to diet and exercise to improve glycemic control in adult patients with Type II Diabetes.||25.9.14|
|27||Sorafenib tosylate tablet 200mg (Additional indication)||For the treatment of patients with locally advanced or metastatic differentiated thyroid carcinoma refractory to radioactive iodine.||25.9.14|
|28||Deferasirox Dispersible tablet 100/400mg (Additional indication)||Treatment of chronic iron overload in patients with non-transfusion dependent thalassemia (NTDT) syndromes aged 10 years and older.||26.9.2014|
|29||IMATINIB mesilate100/400mg tablets and 100 mg capsules (Additional indication)||Treatment of Paediatric patients with newly diagnosed Philadelphia chromosome positive acute LymphoblasticLeukaemia (Ph+ALL) integrated with chemotherapy||09-09-2014|
|30||Tapentadol Extended release tablet 100/150/200mg (Additional strength)||For use in in-patients under hospital setting for severe acute pain for a period not exceeding 5 days||9.12.13|
|31||Olanzapine pamoate Prolonged release powder for suspension for I.M injection (combi pack)
Each combipack contains
a. Vial of Olanzapine pamoate Prolonged release powder for suspension. Each vial contains: Olanzapine pamoate monohydrate eq to Olanzapine….. 210mg/300mg/405mg. After reconstituton each mL of suspension contains 150mg.
b. Vial of vehicle: 3mL clear, colourless to slight yellow solution contains: Manitol IP…. 5.070%w/v
Sodium carboxymethyl cellulose IP…. 0.770% w/v Polysorbate 80 IP….. 0.025%w/v
Water for injection….q.s. to 100%
|For the treatement of schizophrenia||14.10.14|
|32||Rivastigmine transdermal patch. EachTranstermal patch of 15cm2 contains Rivastigmine 27mg (Additional indication)||For the treatment of patients with severe dementia of the Alzheimer’s type||28-10-2014|
|33||Dabigatran Etexilate Mesilate hard gelatin capsule 75/110/150mg (Additional Indication)||1. Treatment of acute deep vein thrombosis (DVT) and /or pulmonary embolism (PE) and prevention of related death. 2.Prevention of recurrent deep vein thrombosis (DVT) and /or pulmonary embolism (PE) and related death||17.11.14|
|34||Pegasperagase 3,750 IU/5 mL||Indicated as a component of multi agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to asparaginase||07 03 2014|
|35||Tulobuterol Transdermal Patch 0.5 mg/ 1.0 mg /2.0 mg||For treatment of patients with Asthma and COPD without co-morbidity||24 04 14|
|36||Azacitidine 100 mg / vial||For the treatment of adult patients with all subtypes of Myelodysplastic Syndrome||29 04 14|
|37||Azacitidine||For the treatment of adult patients with all subtypes of Myelodysplastic Syndrome||23 07 14|
|38||Regorafenib film coated tablet 40 mg||For the “treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan-base chemotherapy, ananti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy”.||01 07 14|
|39||Roflumilast Tab 500 mcg||For the treatment of severe chronic obstructive pulmonary disease (COPD)(FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.||17 07 14|
|40||Dimethyl Fumarate delayed release 120 mg/240 mg Tablet||For ” Relapsing remitting multiple sclerosis”||27 08 14|
|41||Alogliptin Tablet 6.25 mg/12.5 mg/ 25 mg||” To improve glycemic control in combination with other glucose lowering medicinial products including insulin when these together with diet and exercise, do not provide adequated glycemic control or as monotherapy as adjunct to diet and exercise to improve glycemic control in adults aged 18 years or older with type 2 Diabetic mellitus.”||27 08 14|
|42||Axitinib Tablet 1mg/5mg||For the “ treatment of advanced renal cell carcinoma after failure of one prior systemic therapy”||18.09.14|
|43||Ulinastatin Injection||For the treatment of mild to severe acute pancreatitis.||19.09.14|
|44||Canagliflozin Tablet 100/300mg||“Indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type-2 Diabetic Mellitus”.||17.11.14|
Drugs Banned in other Countries But Available in India
Though each country has its own list of banned drugs, it is worrisome that some drugs that are banned in other countries for proven adverse effects are still available in the Indian market. Some of these drugs are available over – the – counter and people may take it without realizing the risk. A note of caution on these drugs could help patients in deciding whether they want to take the drug. Some of these drugs are:
Phenylpropanolamine is commonly found in cold and cough medications in India. It was also used to treat obesity in the US where it was found to increase the risk of hemorrhagic stroke (stroke due to a bleed in the brain). It also had the potential to worsen psychiatric problems. Though the dose used in cough and cold medicines is lower than that used in obesity, people buying the medication especially over the counter should be made aware of these adverse effects. This drug has come under the scanner and may soon be banned in India.
Analgin is a painkiller. It has been banned in some countries since it carries the risk of agranulocytosis (condition where the bone marrow does not produce certain types of white blood cells). Beside, safer painkillers that are equally effective are easily available and there is no need to take such as serious risk. Analgin itself is not banned in India but the combination of analgin with any other drug is banned.
Oxyphenbutazone is a painkiller belonging to the same class of drugs as analgin. It has been banned in many countries since it causes bone marrow depression and other side effects. Its combination with any other drug is banned in India.
Nimesulide is a painkiller that was not introduced in the American, UK or Australian market but is widely used in India. It has been found to cause liver failure and hence has been banned in some countries. Children with viral infection could be particularly susceptible. However, the ban has not been implemented even in children in India.
Cisapride is a drug that increases the motility of the gastrointestinal tract. It is used to treat acidity and constipation. It may cause arrhythmia when used in high doses or when combined with other drugs like erythromycin and ketoconazole; hence it is banned in some countries. Its use in India is under the scanner and it may soon face a ban.
Furazolidone and Nitrofurazone
Furazolidone acts against some bacteria and protozoa that cause diarrhea. It is used alone as well as with other drugs such as metronidazole. It has been banned in some countries since it belongs to a class of drugs that could cause cancer. The combination of loperamide with furazolidone is banned in India.
Nitrofurazone is an antibacterial cream that belongs to the same class of drugs as furazolidone, thus there is a chance that it could also cause cancer. Hence it is banned in some countries.
Cerivastatin in a cholesterol lowering drug similar to atorvastatin. It was withdrawn since it caused several cases of rhabdomyolysis (damage to muscles) following which patients suffer from kidney failure. Unfortunately, it is still available in India.
Phenolphthalein is a stimulant purgative. It produced cancers when tested in mice as well as damage to genes. Hence it has been banned in some countries.
Quinodochlor is an amoebicidal drug effective against diarrhea caused by amoebae. It caused a serious side effect called subacute myelo – optic neuropathy, initially seen in Japanese, a condition that caused nerve damage and loss of sight.
Tegaserod is a drug that is used to treat patients with irritable bowel syndrome with predominantly constipation. It was withdrawn from the market since patients taking this drug showed increased incidence of heart attack and stroke.
Human Placental extract
Human placental extract is used in the cosmetic industry in the form of lotion, gel and injection. It is not permitted in some countries since it can transmit diseases to the user. It is under the scanner and may be banned in the future.
Thioridazine is an antipsychotic drug. It causes adverse effects like arrhythmia (abnormal heart rhythm), eye damage, and a condition called neuroleptic malignant syndrome.
Pergolide is a drug used for the treatment of Parkinson’s disease. It has been withdrawn from some countries since it causes damage to heart valves.